Biocon Unit Gets USFDA Nod For Generic Rifaximin Tablets Used To Treat IBS-D
On Tuesday, Biocon Ltd. said its unit has received approval from the US health regulator for a genetic anti-bacterial medication. The approval was given to Biocon's unit in partnership with Carnegie Pharmaceuticals LLC
"This is to inform you that Biocon Pharma Ltd., a wholly owned subsidiary of the Company, in partnership with Carnegie Pharmaceuticals LLC, received tentative approval from the U.S. Food and Drug Administration (U.S. FDA) for the ANDA for Rifaximin Tablets, 550 mg," the company informed the exchanges.
Rifaximin tablets are indicated for reducing the risk of overt hepatic encephalopathy (HE) recurrence and to treat irritable bowel syndrome with diarrhoea (IBS-D) in adults.
Biocon's 4 global businesses include generics, biosimilars, research services and novel biologics, the company's official website said. The company also said that it is steadfastly investing in developing novel therapies for diabetes, oncology and immunology.
Earlier on Oct. 6, the company announced that its Board of Directors will meet on Nov. 11 to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025.
In line with the company's Code of Conduct for Prevention of Insider Trading and SEBI's Insider Trading Regulations, the trading window has been closed from October 1 to November 13, 2025, and will reopen on Friday, November 14, 2025.
The scrip rose as much as 0.96% to Rs 351.10 apiece. It gave up gains to trade 0.13% lower at Rs 347.30 apiece, as of 02:03 p.m. This compares to a 0.50% advance in the NSE Nifty 50 Index.
It has risen 2.15% in the last 12 months. Total traded volume so far in the day stood at 0.44 times its 30-day average. The relative strength index was at 42.
Out of 18 analysts tracking the company, 10 maintain a 'buy' rating, three recommend a 'hold,' and five suggest 'sell,' according to Bloomberg data. The average 12-month consensus price target implies an upside of 10.3%
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
